Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genmab
Genmab
Hackensack Meridian Health
University of Chicago
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
University of California, Davis
University of California, Davis
Vitebsk Regional Clinical Cancer Centre
University of California, San Diego
Institute of Hematology & Blood Diseases Hospital, China
Celgene
University of Wisconsin, Madison
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Abramson Cancer Center at Penn Medicine
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
TG Therapeutics, Inc.
Hackensack Meridian Health
TG Therapeutics, Inc.
Weill Medical College of Cornell University
German CLL Study Group
Celgene
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Gilead Sciences
Mayo Clinic
Mayo Clinic
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Mayo Clinic
M.D. Anderson Cancer Center
Celgene
University of Wisconsin, Madison
Celgene
Alliance for Clinical Trials in Oncology
Celgene
M.D. Anderson Cancer Center
Scripps Health
Gruppo Italiano Malattie EMatologiche dell'Adulto
Gruppo Italiano Malattie EMatologiche dell'Adulto
Georgetown University
Celgene
M.D. Anderson Cancer Center